BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dabrafenib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dabrafenib\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06653517-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT06653517)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: Clinical Study of Neoadjuvant Tar
 geted Therapy for Ameloblastoma\nEstimated primary completion: 31 December
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0665351
 7
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739395-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT06739395)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: Precision Medicine Trial Based on
  Molecular Matching Therapy for Patients With Standard Treatment Exhaustio
 n\nEstimated primary completion: 31 December 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT06739395
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06195228-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dabrafenib: Phase 4 readout est. (NCT06195228)
DESCRIPTION:Dabrafenib\, phase 4.\nStudy: A Retrospective and Prospective R
 eal-world Study of Molecular Typing in the Treatment of Advanced Thyroid C
 ancer\nEstimated primary completion: 31 December 2026. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06195228
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06079333-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT06079333)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: NEO- and Adjuvant Targeted Therap
 y in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)\nEsti
 mated primary completion: 1 January 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06079333
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02196181-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270315
DTEND;VALUE=DATE:20270316
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02196181)
DESCRIPTION:Dabrafenib\, phase 2\, Melanoma.\nStudy: Testing Two Different 
 Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has
  Spread\nEstimated primary completion: 15 March 2027. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT02196181
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02231775-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270401
DTEND;VALUE=DATE:20270402
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02231775)
DESCRIPTION:Dabrafenib\, phase 2\, Melanoma.\nStudy: Dabrafenib and Trameti
 nib Before and After Surgery in Treating Patients With Stage IIIB-C Melano
 ma With BRAF V600 Mutation\nEstimated primary completion: 1 April 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT02231775
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05585320-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dabrafenib: Phase 1/2 readout est. (NCT05585320)
DESCRIPTION:Dabrafenib\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: A 
 Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic 
 Solid Tumors\nEstimated primary completion: June 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05585320
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04238624-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270620
DTEND;VALUE=DATE:20270621
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT04238624)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: Study of Cemiplimab Combined With
  Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer\nEstim
 ated primary completion: 20 June 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT04238624
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02925234-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02925234)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: The Drug Rediscovery Protocol (DR
 UP Trial)\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT02925234
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04544111-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270902
DTEND;VALUE=DATE:20270903
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT04544111)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: PDR001 Combination Therapy for Ra
 dioiodine-Refractory Thyroid Cancer\nEstimated primary completion: 2 Septe
 mber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT045
 44111
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05525273-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270910
DTEND;VALUE=DATE:20270911
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT05525273)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: Treatment of BRAF ( B-Rapidly Acc
 elerated Fibrosarcoma) Mutated Papillary Craniopharyngioma\nEstimated prim
 ary completion: 10 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT05525273
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03919071-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT03919071)
DESCRIPTION:Dabrafenib\, phase 2\, Glioma.\nStudy: Dabrafenib Combined With
  Trametinib After Radiation Therapy in Treating Patients With Newly-Diagno
 sed High-Grade Glioma\nEstimated primary completion: 30 September 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03919071
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06563999-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT06563999)
DESCRIPTION:Dabrafenib\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Neoa
 djuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harb
 oring Rare Mutations.\nEstimated primary completion: 1 November 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06563999
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06978400-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT06978400)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: A Study of Dabrafenib Plus Cetuxi
 mab/Panitumumab With FOLFOX in the First Line of Therapy in People With Me
 tastatic Colorectal Cancer\nEstimated primary completion: 10 November 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06978400
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06967155-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271110
DTEND;VALUE=DATE:20271111
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT06967155)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: A Study of Irinotecan With Dabraf
 enib Plus Trametinib and Anti-EGFR in the Second Line of Therapy in People
  With Metastatic Colorectal Cancer\nEstimated primary completion: 10 Novem
 ber 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0696
 7155
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07506109-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT07506109)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: A Phase II Study of Sintilimab Co
 mbined With Ipilimumab N01\, Cetuximab and Dabrafenib in Patients With Mic
 rosatellite-Stable\, BRAF V600E-Mutated Metastatic Colorectal Cancer\nEsti
 mated primary completion: December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07506109
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02910700-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271208
DTEND;VALUE=DATE:20271209
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02910700)
DESCRIPTION:Dabrafenib\, phase 2\, Melanoma.\nStudy: Nivolumab With Trameti
 nib and Dabrafenib\, or Encorafenib and Binimetinib in Treating Patients W
 ith BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma\nEstimat
 ed primary completion: 8 December 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02910700
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01989585-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dabrafenib: Phase 1/2 readout est. (NCT01989585)
DESCRIPTION:Dabrafenib\, phase 1/2\, Melanoma.\nStudy: Testing the Addition
  of Navitoclax to the Combination of Dabrafenib and Trametinib in People W
 ho Have BRAF Mutant Melanoma\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT01989585
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02693535-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02693535)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: TAPUR: Testing the Use of Food an
 d Drug Administration (FDA) Approved Drugs That Target a Specific Abnormal
 ity in a Tumor Gene in People With Advanced Stage Cancer\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT02693535
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02465060-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT02465060)
DESCRIPTION:Dabrafenib\, phase 2\, Melanoma.\nStudy: Targeted Therapy Direc
 ted by Genetic Testing in Treating Patients With Advanced Refractory Solid
  Tumors\, Lymphomas\, or Multiple Myeloma (The MATCH Screening Trial)\nEst
 imated primary completion: 31 December 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT02465060
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07010393-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dabrafenib: Phase 4 readout est. (NCT07010393)
DESCRIPTION:Dabrafenib\, phase 4.\nStudy: Genotype-Driven Neoadjuvant Thera
 py for Locally Advanced Thyroid Cancer: A Real-World Cohort Study\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07010393
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07022834-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280601
DTEND;VALUE=DATE:20280602
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT07022834)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: Real-world Study of Darafenib or 
 Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans C
 ell Histiocytosis in Children\nEstimated primary completion: 1 June 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07022834
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04903119-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20280701
DTEND;VALUE=DATE:20280702
SUMMARY:Dabrafenib: Phase 1 readout est. (NCT04903119)
DESCRIPTION:Dabrafenib\, phase 1\, Melanoma.\nStudy: Nilotinib Plus Dabrafe
 nib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma\nEstimate
 d primary completion: 1 July 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04903119
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04675710-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT04675710)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: Pembrolizumab\, Dabrafenib\, and 
 Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thy
 roid Cancer\nEstimated primary completion: 30 October 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04675710
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06819605-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Dabrafenib: Phase 2/3 readout est. (NCT06819605)
DESCRIPTION:Dabrafenib\, phase 2/3.\nStudy: Neoadjuvant Therapy With Conser
 vative Surgery vs. Up-front Conservative Surgery for BRAF V600E-Mutated Am
 eloblastoma\nEstimated primary completion: 30 October 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT06819605
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06712875-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dabrafenib: Phase 1/2 readout est. (NCT06712875)
DESCRIPTION:Dabrafenib\, phase 1/2\, Glioma.\nStudy: MAPK Inhibition Combin
 ed With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas\nEstimated pri
 mary completion: December 2028. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06712875
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07886905-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20290408
DTEND;VALUE=DATE:20290409
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT07886905)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: Pulsed Stereotactic Ablative Radi
 otherapy (PULSAR) With Systematic Therapy for Thyroid Cancer\nEstimated pr
 imary completion: 8 April 2029. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/dabrafenib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07886905
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05722886-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Dabrafenib: Phase 2/3 readout est. (NCT05722886)
DESCRIPTION:Dabrafenib\, phase 2/3.\nStudy: DETERMINE (Determining Extended
  Therapeutic Indications for Existing Drugs in Rare Molecularly Defined In
 dications Using a National Evaluation Platform Trial) - Master Screening P
 rotocol\nEstimated primary completion: October 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT05722886
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07440290-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20291031
DTEND;VALUE=DATE:20291101
SUMMARY:Dabrafenib: Phase 2/3 readout est. (NCT07440290)
DESCRIPTION:Dabrafenib\, phase 2/3\, Glioma.\nStudy: DETERMINE Trial Treatm
 ent Arm 07: Dabrafenib in Combination With Trametinib in Adult\, Paediatri
 c and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancer
 s.\nEstimated primary completion: October 2029. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07440290
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05159245-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20311125
DTEND;VALUE=DATE:20311126
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT05159245)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: The Finnish National Study to Fac
 ilitate Patient Access to Targeted Anti-cancer Drugs\nEstimated primary co
 mpletion: 25 November 2031. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/dabrafenib#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05159245
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07110246-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20320331
DTEND;VALUE=DATE:20320401
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT07110246)
DESCRIPTION:Dabrafenib\, phase 2\, Glioma.\nStudy: Dabrafenib and Trametini
 b for BRAF V600 Mutant Low-Grade Gliomas\nEstimated primary completion: 31
  March 2032. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dabrafen
 ib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7110246
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03340506-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20321228
DTEND;VALUE=DATE:20321229
SUMMARY:Dabrafenib: Phase 4 readout est. (NCT03340506)
DESCRIPTION:Dabrafenib\, phase 4\, Non-Small Cell Lung Cancer.\nStudy: Dabr
 afenib and/or Trametinib Rollover Study\nEstimated primary completion: 28 
 December 2032. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dabraf
 enib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T03340506
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06119789-2236@assetmemo.bio
DTSTAMP:20261121T004039Z
DTSTART;VALUE=DATE:20331130
DTEND;VALUE=DATE:20331201
SUMMARY:Dabrafenib: Phase 2 readout est. (NCT06119789)
DESCRIPTION:Dabrafenib\, phase 2.\nStudy: Precision Cancer Therapy in Rare 
 Cancers\nEstimated primary completion: 30 November 2033. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/dabrafenib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06119789
URL:https://assetmemo.bio/drug/dabrafenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
